Is Cerebrolysin FDA approved?

Cerebrolysin is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Pinealon FDA approved?

Pinealon is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Cerebrolysin administered in research settings?

In research settings, Cerebrolysin is typically administered via the intravenous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

How is Pinealon administered in research settings?

In research settings, Pinealon is typically administered via the intranasal or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cerebrolysin vs Pinealon

Peptide Comparison

Cerebrolysin vs Pinealon

Name: Cerebrolysin vs Pinealon — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Neuro & Cognitive peptides.

Cerebrolysin

FPF 1070

CognitiveInvestigationalResearch Only

Half-life: Varies by component

33 providers listed

Full Cerebrolysin profile →

Pinealon

EDR tripeptide

CognitiveNot EvaluatedResearch Only

Half-life: Unknown

27 providers listed

Full Pinealon profile →

Bottom line

Cerebrolysin carries stronger published evidence (Meta-analysis, 5 key studies) than Pinealon (In vitro, 1); both are research compounds.

Quick Verdict

Cerebrolysin

Pinealon

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Cerebrolysin
Further along in FDA review	Cerebrolysin
Lower typical price per mg	Cerebrolysin
More provider options (33 vs 27)	Cerebrolysin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cerebrolysin

Pinealon

Mechanism Family

Neuro & Cognitive

Half-life

Varies by component

Unknown

FDA Status

investigational

not evaluated

Admin Routes

intravenous, intramuscular

intranasal, subcutaneous

Availability

Research Only

Providers

33 listed

27 listed

Avail. Notes

Neuropeptide mixture approved in EU/Asia but NOT FDA-approved. Phase 2/3 US trials for Alzheimer's disease and stroke with active IND. No NDA filed. Research use in US.

Russian peptide bioregulator (Glu-Asp-Arg) from pineal gland, Khavinson Institute. Studied for visual function and longevity. No FDA approval, no NDA or IND. Research chemical in US.

Research Evidence

Cerebrolysin

Meta-analysis · 5 key studies · most recent 2026

Pinealon

In vitro · 1 key study · most recent 2017

Research Citations

Cerebrolysin

Meta-analysis2019 · Cochrane Database of Systematic Reviews

Cerebrolysin for vascular dementia

Cohort2026 · Asian J Neurosurg

Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Mon…

RCT2024 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a thre…

In vitro2026 · Cells

Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothel…

+1 more

Pinealon

In vitro2017 · Bulletin of Experimental Biology and Medicine

Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease

About Cerebrolysin

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

Research Areas

neuroprotectionneuroplasticitymemory improvementcognitive recovery

About Pinealon

Glu-Asp-Arg tripeptide; penetrates blood-brain barrier; modulates gene expression in neurons; reduces oxidative stress in brain tissue

Research Areas

neuroprotectionantioxidant (CNS)sleep improvementanti-aging (brain)

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cerebrolysin

Reported (Unverified — Pending Clinical Review)

epilepsyrenal failureporcine protein allergy

No established clinical contraindications

Pinealon

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

Cerebrolysin

$0.83/mg

$0.82 – $0.83 range

9 vendors

View price index →Find providers →

Pinealon

$3.51/mg

$2.99 – $4.49 range

38 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Cerebrolysin

33 listed

Browse directory →

Providers offering

Pinealon

27 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cerebrolysin vs Pinealon — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/cerebrolysin/pinealon

https://peptidebase.io/peptides/compare/cerebrolysin/pinealon Methodology License Download JSON Download CSV